- Home
- STAA vs SVRA Comparison
STAA vs SVRA Comparison
Compare STAA & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STAA | SVRA |
|---|---|---|
| Founded | 1982 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 1995 | 2009 |
Fundamental Metrics
Financial Performance| Metric | STAA | SVRA |
|---|---|---|
| Price | $25.21 | $4.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 9 |
| Target Price | ★ $27.67 | $11.06 |
| AVG Volume (30 Days) | 566.3K | ★ 2.4M |
| Earning Date | 11-04-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $239,442,000.00 | N/A |
| Revenue This Year | $39.61 | N/A |
| Revenue Next Year | $7.86 | $4,336.88 |
| P/E Ratio | $73.43 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.59 | $3.95 |
| 52 Week High | $35.87 | $7.01 |
Technical Indicators
Market Signals| Indicator | STAA | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 60.49 | 51.01 |
| Support Level | $21.56 | $4.73 |
| Resistance Level | $26.58 | $5.47 |
| Average True Range (ATR) | 1.24 | 0.32 |
| MACD | 0.35 | 0.02 |
| Stochastic Oscillator | 50.68 | 70.15 |
Price Performance
Historical ComparisonAbout STAA STAAR Surgical Company
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company offers two types of products: Implantable Collamer lenses (ICL), which are used in refractive surgery. The company generates almost all of its revenue from the sale of its ICL products. Geographically, the company generates key revenue from Foreign sales.
About SVRA Savara Inc.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).